CA2461812C — 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
Assigned to Allergan Inc · Expires 2011-09-20 · 15y expired
What this patent protects
The present invention relates to organic molecules of Formula I capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. (see formula I)
USPTO Abstract
The present invention relates to organic molecules of Formula I capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. (see formula I)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.